Literature DB >> 2936963

Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity.

B P Wallner, R J Mattaliano, C Hession, R L Cate, R Tizard, L K Sinclair, C Foeller, E P Chow, J L Browing, K L Ramachandran.   

Abstract

The anti-inflammatory action of glucocorticoids has been attributed to the induction of a group of phospholipase A2 inhibitory proteins, collectively called lipocortin. These proteins are thought to control the biosynthesis of the potent mediators of inflammation, prostaglandins and leukotrienes, by inhibiting the release of their common precursor, arachidonic acid, a process that requires phospholipase A2 hydrolysis of phospholipids. Lipocortin-like proteins have been isolated from various cell types, including monocytes, neutrophils and renal medullary cell preparations. The predominant active form is a protein with an apparent relative molecular mass (Mr) of 40,000 (40K). These partially purified preparations of lipocortin mimic the effect of steroids, and mediate anti-inflammatory activity in various in vivo model systems. Using amino-acid sequence information obtained from purified rat lipocortin, we have now cloned human lipocortin complementary DNA and expressed the gene in Escherichia coli. Our studies confirm that lipocortin is a potent inhibitor of phospholipase A2 activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936963     DOI: 10.1038/320077a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  133 in total

1.  Functional genomics in gastroenterology.

Authors:  S Schreiber; J Hampe; H Eickhoff; H Lehrach
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

2.  Autoantibodies to recombinant lipocortin-1 in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  N J Goulding; M R Podgorski; N D Hall; R J Flower; J L Browning; R B Pepinsky; P J Maddison
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

Review 3.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

4.  In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Gut       Date:  1987-09       Impact factor: 23.059

5.  "Tissue" transglutaminase is specifically expressed in neonatal rat liver cells undergoing apoptosis upon epidermal growth factor-stimulation.

Authors:  M Piacentini; F Autuori; L Dini; M G Farrace; L Ghibelli; L Piredda; L Fesus
Journal:  Cell Tissue Res       Date:  1991-02       Impact factor: 5.249

Review 6.  Annexins: calcium-binding proteins of multi-functional importance?

Authors:  J Römisch; E P Pâques
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

7.  Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase.

Authors:  M Goppelt-Struebe; D Wolter; K Resch
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

8.  Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain.

Authors:  Xiao-Min Wang; Tian-Xia Wu; May Hamza; Edward S Ramsay; Sharon M Wahl; Raymond A Dionne
Journal:  Pain       Date:  2006-10-27       Impact factor: 6.961

9.  Functional implications of nitric oxide produced by mitochondria in mitochondrial metabolism.

Authors:  C Giulivi
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

10.  Translocation of annexin I to plasma membranes and phagosomes in human neutrophils upon stimulation with opsonized zymosan: possible role in phagosome function.

Authors:  M Kaufman; T Leto; R Levy
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.